Level Four Advisory Services LLC Lowers Stock Position in Eli Lilly and Company $LLY

Key Points

• Level Four Advisory Services LLC decreased its stake in Eli Lilly and Company by 5.8%, owning 6,443 shares valued at $5,322,000 after selling 397 shares.
• Eli Lilly reported a quarterly earnings per share (EPS) of $6.31, exceeding estimates and marking a 37.6% increase in revenue year-over-year.
• The company announced a quarterly dividend of $1.50 per share, with a payment date set for September 10th, contributing to an annualized dividend yield of 0.9%.

Level Four Advisory Services LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,443 shares of the company's stock after selling 397 shares during the quarter. Level Four Advisory Services LLC's holdings in Eli Lilly and Company were worth $5,322,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Erste Asset Management GmbH boosted its stake in shares of Eli Lilly and Company by 51.5% in the 1st quarter. Erste Asset Management GmbH now owns 43,617 shares of the company's stock valued at $35,876,000 after purchasing an additional 14,819 shares during the last quarter. HMS Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $1,431,000. Vertex Planning Partners LLC boosted its stake in shares of Eli Lilly and Company by 5.9% in the 1st quarter. Vertex Planning Partners LLC now owns 632 shares of the company's stock valued at $522,000 after purchasing an additional 35 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $330,000. Finally, Heritage Financial Services LLC boosted its stake in shares of Eli Lilly and Company by 3.6% in the 1st quarter. Heritage Financial Services LLC now owns 1,886 shares of the company's stock valued at $1,558,000 after purchasing an additional 66 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. Guggenheim reduced their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Stock Up 0.1%

NYSE LLY traded up $0.9090 on Friday, hitting $710.7290. 3,217,264 shares of the company were exchanged, compared to its average volume of 6,973,298. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a fifty day moving average of $754.70 and a 200-day moving average of $790.90. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.48. The company has a market cap of $672.68 billion, a PE ratio of 46.45, a PEG ratio of 0.99 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.